Nuvalent presses ahead in ALK
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
Amgen goes pivotal with subcutaneous Blincyto
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
Sutro goes back to work
The restructured biotech’s new lead project enters phase 1.
Genmab pushes rina-S into its third phase 3
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
Mersana gets its rescue bid
But the Day One deal is still 29% below where the shares stood at the start of this year.
